An official ATS statement: hepatotoxicity of antituberculosis therapy.
about
Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TBChallenges in the diagnosis & treatment of miliary tuberculosisRecent developments in treatment of latent tuberculosis infectionDrug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An OverviewHepatic manifestations of non-steroidal inflammatory bowel disease therapyTreatment of Drug Susceptible Pulmonary TuberculosisTuberculosis: From an incurable scourge to a curable disease - journey over a millenniumChallenging issues in tuberculosis in solid organ transplantationPharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Hepatotoxicity from antituberculous therapy in the elderly: a systematic reviewTuberculosis in pregnant and postpartum women: epidemiology, management, and research gapsTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityAssessment of treatment response in tuberculosisPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsIncidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in ChinaStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisPotential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionLiver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in TanzaniaPharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysisCytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohortField evaluation of a prototype paper-based point-of-care fingerstick transaminase testThe incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South AfricaAnalysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control studyCost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort StudyWild Edible Fruit of Prunus nepalensis Ser. (Steud), a Potential Source of Antioxidants, Ameliorates Iron Overload-Induced Hepatotoxicity and Liver Fibrosis in MicePredictors of Prolonged TB Treatment in a Dutch Outpatient SettingToxicity study of Lauha Bhasma (calcined iron) in albino ratsDrug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysisAntitubercular therapy in patients with cirrhosis: challenges and optionsFactors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004.Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria.Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.Clinical review: tuberculosis on the intensive care unit.Risk for latent and active tuberculosis in Germany.Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999-2013
P2860
Q21245662-79530800-2785-4833-A1CE-F7A1AC189F83Q24630463-B0886E72-286B-4C99-8C1E-FEC967421EA3Q24630473-42DA74EE-7E36-4C3D-938D-8BAAD7E857B2Q26767516-51BD7326-9582-413A-BCEA-1BDB29E6AA27Q26773684-5E1F6F6D-2315-40B6-B84E-3460D74B4B64Q26801605-107EC566-6E27-438F-A81F-5D32FA40191BQ26865560-70532A33-E088-42A6-895F-0FF37BDF786BQ26998877-5B85DFCF-AEF6-4C93-B6E3-5198B769386CQ27011622-53A94D37-7ED3-4369-BF0A-5F5EED957FF5Q27022370-B1C0FFFA-063B-46D7-B4CA-C83038FD0793Q27022592-F2214610-2578-4EF3-9933-6C8B26276BA1Q28087473-D23083B3-B345-48BA-A9D6-08D8F1A6204BQ28384421-83CC1F9A-93C2-4D97-B326-88E8DF2E67B5Q28478275-F3156922-2B14-4B55-9719-B1B74E973003Q28478918-F5A3A9DA-6F26-4AEB-B4F6-9CAC627AE02CQ28478920-2DF1FF72-97EC-4741-ADBC-98868BEF70BAQ28479103-7ACE94D9-08AA-4C82-8C0F-94C196D4576FQ28481272-6B924FCC-0C49-497F-9784-CFD7F7F11912Q28484468-9A8D6D2B-6B9B-43D0-83C9-F4B0F1AEDB97Q28486869-DD4CEC78-7AB3-495A-BC2C-77CFE47621C6Q28533930-3977ECD3-DC94-4F2C-BEFA-EAE058E7CDFDQ28539060-467F459F-EA46-4FE8-B229-5AAF206E04E4Q28543376-538F423C-3D3C-4663-B9E8-7F368F8EC320Q28544718-5A0702F7-F6B2-4884-A93E-1E5BBB1262BAQ28547335-52FA77CB-1B22-417D-9317-6557349C4416Q28551313-F2BA8088-40C5-4D42-837D-A7C5B910A1F6Q28553471-F25D99A2-DE4F-4924-8C4A-676DE76257A9Q28603559-C4B39C83-6DF2-471A-B8E4-F091BC0CF263Q30241648-D55793B5-4A72-4BCE-B779-7E9FBBF8FB13Q30277969-37A8F70E-3017-45B4-B816-096F7E851B40Q30498213-AADB65D9-E02A-4297-8B53-CA770FD1A967Q30582650-AB9D43CD-FF72-46F2-A6B9-31A4F12E5C54Q33532816-FBF36D72-9098-479C-B0FC-0952430FE3B6Q33626827-7010B7A5-2254-42FC-854E-9BF91F48A688Q33662605-E31FFAAC-6312-4A3A-AEA8-04D9AA20116FQ33716365-309D2979-5D32-4369-BDB7-77CF765F8D26Q33746114-CF4A8E5F-21E0-4312-A279-00032A7B82E0Q33750370-27D75AB5-64E8-4BB1-8CDD-0698EB613B3EQ33845283-46BCAAE5-6B1F-42CB-8F42-05009B37BEE8Q33867704-EC2505B1-4F5D-4938-8F89-8F1ECCF49D93
P2860
An official ATS statement: hepatotoxicity of antituberculosis therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@ast
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@en
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@nl
type
label
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@ast
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@en
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@nl
prefLabel
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@ast
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@en
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@nl
P2093
P1476
An official ATS statement: hepatotoxicity of antituberculosis therapy.
@en
P2093
ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee
Charles A Peloquin
Charles M Nolan
David L Cohn
David Nunes
Dorothy B Strader
Fred M Gordin
John A Jereb
John Bernardo
Jussi J Saukkonen
P304
P356
10.1164/RCCM.200510-1666ST
P407
P577
2006-10-01T00:00:00Z